Status:
UNKNOWN
Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Arterial Thrombosis
Eligibility:
All Genders
18-75 years
Brief Summary
Recombinant staphylokinase (r-SAK) is a third-generation thrombolytic agent produced by genetic engineering technology in 1985, which has better thrombolytic effect than streptokinase (SK) and urokina...
Detailed Description
Currently, the most important treatment for thrombus and related cardiovascular diseases is prevention, but in the case of long-term thrombosis, the main treatment options include balloon catheters, s...
Eligibility Criteria
Inclusion
- For CAD patients:
- Age 18-75 years old, body weight ≥45kg, regardless of gender;
- Patients with suspected coronary artery disease scheduled for coronary angiography or interventional therapy.
- Take aspirin and ticagrelor maintenance dose ≥3 days, or loading dose of aspirin (300mg) and ticagrelor (180mg) ≥12 hours;
Exclusion
- Previous thrombolytic therapy with r-SAK;
- A previous diagnosis of Staphylococcus aureus infection;
- Those who are enrolled in other clinical trials;
- Those who were deemed ineligible by other investigators.
- For healthy volunteer:
- Inclusion Criteria:
- 1\. Age 18-75 years old, body weight ≥45kg, regardless of gender;
Key Trial Info
Start Date :
October 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05978791
Start Date
October 11 2023
End Date
June 1 2024
Last Update
October 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029